#United States #Lisle #EVERSANA #SUBVENITE® #OWP Pharmaceuticals

OWP Pharmaceuticals and EVERSANA Join Forces for U.S. Launch of SUBVENITE®

In an exciting development for patients dealing with epilepsy and bipolar disorders, OWP Pharmaceuticals has announced a strategic partnership with EVERSANA, a leading provider of commercialization services in the life sciences sector. This collaboration is aimed at launching SUBVENITE® (lamotrigine) oral suspension in the United States following its approval by the U.S. Food and Drug Administration (FDA) on September 16, 2025.

SUBVENITE® is a groundbreaking formulation, marking the first FDA-approved lamotrigine oral suspension available in the U.S. It offers a patient-friendly alternative to traditional tablet forms of medication, making it particularly suitable for those who have difficulties swallowing pills or for whom precise dosing is essential. This shift towards a liquid medication format is a significant step in enhancing treatment accessibility for patients.

The therapy is designed to expand access to epilepsy treatments, with a focus on providing flexibility and convenience. Lamotrigine is well-regarded in the medical community but has predominantly been offered in tablets until now. By introducing a ready-to-use liquid version, SUBVENITE® meets the needs of a diverse patient population, making treatment more manageable and personalized.

To ensure a successful market entry, EVERSANA is implementing a comprehensive suite of services which includes field deployment, data analytics, and co-pay support. This initiative represents a continuum of their interaction, following a broader commercialization partnership established back in January 2022 between EVERSANA and OWP Pharmaceuticals.

Gregory Skalicky, President of EVERSANA, emphasized the ongoing struggles many patients face in accessing effective treatment options. "Market access challenges continue to be the major hurdle for patients looking for new treatment options. Together with OWP Pharmaceuticals, we're removing barriers and helping patients find new hope," he stated.

OWP Pharmaceuticals was founded in 2014 and has since dedicated itself to innovation within the pharmaceutical landscape, particularly focusing on neuroscience. Their commitment doesn't stop at U.S. borders; OWP is actively engaged in global initiatives through a partnership with the ROW Foundation, which concentrates on humanitarian efforts for those suffering from epilepsy worldwide. An eye-opening fact is that nearly 80% of individuals with epilepsy live in underdeveloped regions where treatment options are scant.

Reflecting on the significance of this partnership, Scott Boyer, Founder and President of OWP Pharmaceuticals, remarked, "Working with EVERSANA to support commercialization efforts in the U.S. is an important milestone for patients. But our vision continues to be greater; we aspire that every epilepsy patient globally has access to medications through both OWP Pharma and the ROW Foundation as part of the Pharmaceutical Social Enterprise®."

As the anticipation builds for the roll-out of SUBVENITE®, OWP Pharmaceuticals remains committed to ensuring that no patient is left behind in receiving effective therapies. With a dedication to innovation and global outreach, they are paving the way for a brighter future for those affected by epilepsy and related conditions.

For further information about OWP Pharmaceuticals and their products, visit www.owppharma.com.

About EVERSANA

EVERSANA® is recognized as a preeminent independent service provider for the life sciences industry, delivering comprehensive solutions designed with the patient experience at their core. The company serves over 650 organizations, ranging from innovative startups to established pharmaceutical giants. To learn more about EVERSANA, you can visit their website eversana.com or connect with them on LinkedIn and X.

About OWP Pharmaceuticals

Based in Lisle, IL, OWP Pharmaceuticals is dedicated to developing and commercializing innovative oral liquid formulations in the field of neuroscience. Their mission extends globally as they partner with the ROW Foundation to improve healthcare access for individuals with epilepsy in underserved communities.

For media inquiries regarding EVERSANA, reach out to Matt Braun at [email protected]. For inquiries concerning OWP Pharmaceuticals, please contact them directly via their media channels.